DBVT

DBVT

USD

DBV Technologies S.A. American Depositary Shares

$8.530-0.080 (-0.929%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
फ्रांस

मूल्य चार्ट

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$8.610

उच्च

$9.350

कम

$8.400

मात्रा

0.01M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

239.0M

उद्योग

जैव प्रौद्योगिकी

देश

France

ट्रेडिंग आँकड़े

औसत मात्रा

0.42M

एक्सचेंज

NCM

मुद्रा

USD

52-सप्ताह रेंज

कम $0.441वर्तमान $8.530उच्च $9.585

संबंधित समाचार

GlobeNewswire

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company

और देखें
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Analyst Upgrades

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

और देखें
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'
GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial

और देखें
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the

और देखें
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।